MedPath

Getting SMART for Pediatric Epilepsy

Phase 2
Recruiting
Conditions
Epilepsy in Children
Interventions
Drug: Placebo
Registration Number
NCT05439876
Lead Sponsor
National Taiwan University Hospital
Brief Summary

The purpose of this study is to evaluate the effect of melatonin for improving sleep in pediatric epilepsy.

Detailed Description

Sleep disturbances are more prevalent in children with epilepsy whose sleep can be disrupted by seizures occurring during the night and/or during the day. Melatonin is a naturally occurring hormone produced in the pineal which regulates sleep-wake cycles and facilitates quality sleep. Therefore, the purpose of this study is to evaluate the effect of melatonin for improving sleep in pediatric epilepsy.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
120
Inclusion Criteria
  • Children aged between 1 and 18 years with a confirmed diagnosis of epilepsy and with sleep problems
Exclusion Criteria
  • Children who are bedridden with limited mobility
  • Children with liver or kidney dysfunction
  • Children on medication for sleep or mood problems within 4 weeks before the baseline clinic visit
  • Adolescent girls who are pregnant or breastfeeding
  • Adolescent girls who have sexual activities but cannot take effective contraceptive measures during the trial

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
PlaceboPlaceboPlacebo
MelatoninMelatoninMelatonin
Primary Outcome Measures
NameTimeMethod
Sleep quality4 weeks

Sleep quality as assessed by actigraphy

Secondary Outcome Measures
NameTimeMethod
Behavioral profile4 weeks

T scores as assessed by Child Behavior Checklist. A T score has a mean of 50 and standard deviation of 10, with higher scores representing more behavioral problems.

Trial Locations

Locations (1)

National Taiwan University Hospital

🇨🇳

Taipei, Taiwan

© Copyright 2025. All Rights Reserved by MedPath